Comparing JAK inhibitors to standard treatment for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial compares a newer type of medication called JAK inhibitors to standard treatments for rheumatoid arthritis (RA). It aims to see which works better for managing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rheumatoid arthritis diagnosed by a doctor using standard criteria from 2010.
- You must be between 18 and 60 years old.
- You cannot have other autoimmune diseases like lupus or psoriatic arthritis.
- You cannot have active infections, cancer, or chronic conditions affecting your blood (like anemia not caused by RA) or kidney disease.
- Your RA must not be in remission (meaning you still have active symptoms).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.